The top 20 highest-paid biopharma CEOs of 2018
As in past years, FiercePharma has tracked yearly data to compile the top CEO pay packages in biopharma, ranging from nearly $60M to $16M in 2018, and they’ve pointed out some notable trends. First, no women made the list. Big Pharma’s only female CEO, GlaxoSmithKline’s Emma Walmsley, fell short with a pay package of $7.75M.
However, some of her Big Pharma peers also fell short. Last year, Novartis’ Vas Narasimhan pulled in $9.9M, Roche’s Severin Schwan pulled in about $11.77M, and Sanofi’s Olivier Brandicourt took a pay cut to $8.2M. But perhaps the biggest change in 2018 is the emergence of biotech CEOs scattered throughout the list. The last trend noted is that company size didn’t exactly correlate with a bigger payday. The top 20 highest-paid biopharma CEOs of 2018 are listed below:
- Stéphane Bancel, Moderna Therapeutics
- Kåre Schultz, Teva
- John Oyler, BeiGene
- Len Schleifer, Regeneron
- John Milligan, Gilead Sciences
- Nick Leschly, Bluebird Bio
- Richard Gonzalez, AbbVie
- Kenneth Frazier, Merck & Co.
- Alex Gorsky, Johnson & Johnson
- Paul Campanelli, Endo
- Ian Read, Pfizer
- Giovanni Caforio, Bristol-Myers Squibb
- Jeffrey Leiden, Vertex Pharmaceuticals
- Robert Bradway, Amgen
- Clay Siegall, Seattle Genetics
- David Ricks, Eli Lilly
- Richard Pops, Alkermes
- Ludwig Hantson, Alexion Pharmaceuticals
- Mark Alles, Celgene
- Michel Vounatsos, Biogen
